INSR and Parkinson disease: At the molecular level, brain IR mainly manifests as impaired downstream signal transduction after insulin receptor activation (Arnold et al., 2018), with evidence of insulin receptor loss in the substantia nigra of PD patients found early on Moroo et al. (1994), Takahashi et al. (1996).